MapLight Therapeutics is pioneering a novel approach to treating central nervous system (CNS) disorders by leveraging advanced technologies to identify and target specific neural circuits associated with various brain conditions. Their discovery platform integrates three key technologies: optogenetics, transcriptomics, and STARmap. Optogenetics allows researchers to manipulate neural circuits in real-time, providing insights into the functions of specific cell types within the brain. Transcriptomics offers a comprehensive analysis of gene expression patterns, enabling the identification of potential therapeutic targets within these circuits. Meanwhile, STARmap technology facilitates the visualization of these targets in intact brain tissue, preserving the spatial architecture of neural circuits and enhancing the understanding of their roles in disease.

The combination of these technologies empowers MapLight to develop targeted therapeutics aimed at improving treatment outcomes for conditions such as schizophrenia, Alzheimer’s disease psychosis, and autism spectrum disorder. Their lead compound, ML-007, is a muscarinic receptor agonist designed to selectively target M1 and M4 receptor subtypes, which are implicated in the pathophysiology of schizophrenia. By pairing ML-007 with a precision-matched peripherally active anticholinergic (PAC) in the formulation ML-007/PAC, MapLight aims to optimize therapeutic efficacy while minimizing side effects. This innovative approach not only addresses the unmet needs in the treatment of CNS disorders but also holds the potential to set a new standard of care in the field.

United States

Maplight is a biopharmaceutical company discovering and developing novel therapeutics for patients with disorders of the central nervous system (CNS).

Maplight Therapeutics

Company Details